UK's C4X Discovery slides on wider FY loss, revenue drop

C4X Discovery Holdings

15/12/2022 12:34

** Shares of C4X Discovery  C4XD.L  down 6% at 19.5p 
    ** British drug discovery company posts wider FY pre-tax
loss of 10.5 mln pounds ($12.94 mln) vs 5.9 mln pounds a year
ago  urn:newsml:reuters.com:*:nFWN3343O5 
    ** FY revenue plunges ~52% to 2.7 mln pounds vs 5.6 mln
pounds reported last year 
    ** C4DX adds that it entered licence deal with drugmaker
AstraZeneca  AZN.L  in November 2022 for its oral small molecule
NRF2 programme 
    ** This third agreement across our partnered programmes with
truly world-renowned industry leader, AstraZeneca, brings the
total potential value of our deals to $1.2 billion - CEO Clive
Dix  
    ** Including session losses, stock has fallen 54% YTD 
($1 = 0.8116 pounds)
 (Reporting by Amna Karimi in Bengaluru)
 ((Amna.Karimi@thomsonreuters.com; +91 8083261226;))